Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?

被引：4
|
作者：
Chen, Ning [2 ,3 ]
Xu, Xiaoling [1 ]
Fan, Yun [1 ]
机构：
[1] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, 1 East Banshan Rd, Hangzhou 310022, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Clin Med Coll 2, Dept Oncol, Hangzhou, Zhejiang, Peoples R China
[3] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, Dept Med Thorac Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷
基金：
中国国家自然科学基金;
关键词：
biomarker; immune checkpoint inhibitor; immunotherapy; oesophageal squamous cell carcinoma; PD-L1; OPEN-LABEL; TUMOR MICROENVIRONMENT; POOR-PROGNOSIS; PHASE-II; CANCER; NIVOLUMAB; CHEMORADIOTHERAPY; CHEMOTHERAPY; CAMRELIZUMAB; EXPRESSION;
D O I：
10.1177/17588359231189420
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Oesophageal squamous cell carcinoma (ESCC) is a kind of malignant tumour with high invasiveness and a poor prognosis. Immunotherapy, especially immune checkpoint inhibitors (ICIs), is a rapidly growing therapeutic method that activates and enhances anti-tumour immunity to treat patients with malignancy. Several clinical trials have confirmed the efficacy of ICIs in the treatment of ESCC. ICIs have been approved for the treatment of patients with ESCC. However, only a subset of patients can obtain excellent benefits from ICI therapy. In recent years, there has been a growing interest in exploring predictive biomarkers of immunotherapy response. In this review, we highlighted the predictive biomarkers for the prognosis of ESCC patients treated with ICIs and pointed out the existing problems and the direction of future research in this field.
引用
收藏
页数：18
相关论文
共 50 条
  • [21] Where are we? Where are we going?
    Stephanie J. Bird
    Science and Engineering Ethics, 2001, 7 : 163 - 164
  • [22] Where We Were, Where We Are, Where We Are Going
    Epstein, Burton S.
    ANESTHESIA AND ANALGESIA, 2011, 113 (03): : 480 - 483
  • [23] Treatment of bulimia nervosa: Where are we and where are we going?
    Mitchell, James E.
    Agras, Stewart
    Wonderlich, Stephen
    INTERNATIONAL JOURNAL OF EATING DISORDERS, 2007, 40 (02) : 95 - 101
  • [24] Sentinel lymph node biopsy in squamous cell carcinoma of the head and neck:: Where we stand now, and where we are going
    Cote, Valerie
    Kost, Karen
    Payne, Richard J.
    Hier, Michael P.
    JOURNAL OF OTOLARYNGOLOGY, 2007, 36 (06): : 344 - 349
  • [25] Where we come from, where we are, where we are going
    Leonhard, Joachim-Felix
    INFORMATION-WISSENSCHAFT UND PRAXIS, 2023, 74 (5-6): : 271 - 274
  • [26] Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
    Carofiglio, Francesca
    Trisciuzzi, Daniela
    Gambacorta, Nicola
    Leonetti, Francesco
    Stefanachi, Angela
    Nicolotti, Orazio
    MOLECULES, 2020, 25 (18):
  • [27] Angiogenesis inhibitors in clinical development; where are we now and where are we going?
    Eskens, FALM
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 1 - 7
  • [28] Angiogenesis inhibitors in clinical development; where are we now and where are we going?
    F A L M Eskens
    British Journal of Cancer, 2004, 90 : 1 - 7
  • [29] Clinical trials with nhe inhibitors: where are we now and where are we going?
    Mentzer, RM
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (01) : 359 - 359
  • [30] The core: Where are we and where are we going?
    Sherry, M
    Best, T
    Heiderscheit, B
    CLINICAL JOURNAL OF SPORT MEDICINE, 2005, 15 (01): : 1 - 2
12345